

IN THE CLAIMS

Pursuant to 37 CFR §1.121(c), this listing of the claims, including the text of the claims, will serve to replace all prior versions of the claims, in the application.

Please amend claims 7, 11, 13, 14, 16 and 17, and cancel claims 10, 12, 15 and 18 without disclaiming their subject matter to read as follows:

1 1. (Previously Presented) A method for controlling chronic inflammation associated with
2 Metabolic Syndrome in an individual having the Metabolic Syndrome, comprising:
3 administering to said individual an effective dosage of a pharmaceutical composition
4 selected from the group consisting of YG-Product, YGG-Product, Purified Leukocyte Dialysate
5 Subfraction, and a combination thereof.

1 2. (Original) The method of claim 1, wherein the chronic inflammation is evidenced by
2 at least one of elevated C-Reactive Protein and elevated serum fibrinogen.

1 3. (Previously Presented) The method of claim 1, wherein the chronic inflammation is
2 evidenced by at least one of elevated platelet count and elevated platelet activity.

1 4. (Previously Presented) The method of claim 1, wherein the individual has at least one
2 condition selected from the group consisting of hypertension, hypercholesterolemia,
3 hypertriglyceridemia, and obesity as part of the Metabolic syndrome.

1 5. (Canceled)

1 6. (Previously Presented) The method of claim 1, wherein the individual has at least one
2 condition selected from the group consisting of obesity, insulin resistance, hypertension,
3 dyslipidemia, impaired glucose tolerance, accompanied by increased acute phase proteins
4 including C-Reactive Protein and fibrinogen.

1 7. (Currently Amended) The method of claim 1, wherein said individual has diabetes
2 mellitus, or coronary artery disease ~~or cancer~~ as part of the Metabolic syndrome.

1 8. (Original) A method for controlling elevated blood glucose level in an individual with
2 inflammation-related metabolic disturbances, comprising:

3 administering to said individual an effective dosage of a composition selected from the
4 group consisting of YG-Product, YGG-Product, Purified Leukocyte Dialysate Subfraction, or a
5 combination thereof.

1 9. (Original) The method of claim 8, wherein the individual has at least one component
2 of the Metabolic Syndrome.

1 10. (Canceled).

1 11. (Currently Amended) A method for mitigating a symptom in a patient having
2 Metabolic Syndrome, said symptom characteristic of chronic inflammation, said patient
3 presenting said symptom, said method comprising administering to the patient a pharmaceutical
4 preparation containing an effective dosage amount of YG-Product, YGG-Product, Purified
5 Leukocyte Dialysate Subfraction, or a combination thereof.

1 12. (Canceled).

1 13. (Currently Amended) The method of ~~claim 12~~ claim 11, wherein said symptom is at
2 least one selected from the group consisting of elevated blood pressure, atherogenic dyslipidemia,
3 abdominal obesity, insulin resistance with or without glucose intolerance, a proinflammatory
4 state, and a prothrombotic state.

1 14. (Currently Amended) A method for mitigating a symptom in a patient having
2 Metabolic Syndrome, said symptom characteristic of an inflammation-related metabolic
3 disturbance, said patient presenting said symptom, said method comprising administering to the
4 patient a pharmaceutical preparation containing an effective dosage amount of YG-Product,
5 YGG-Product, Purified Leukocyte Dialysate Subfraction, or a combination thereof.

1 15. (Canceled).

1 16. (Currently Amended) The method of ~~claim 15~~ claim 14, wherein said component is
2 at least one selected from the group consisting of elevated blood pressure, atherogenic
3 dyslipidemia, abdominal obesity, insulin resistance with or without glucose intolerance, a
4 proinflammatory state, and a prothrombotic state.

1 17. (Currently Amended) A method for deferring the progression of a patient having
2 Metabolic Syndrome from the Metabolic Syndrome including Hypertension, to Diabetes
3 Mellitus, Coronary Heart Disease, or Cancer, said method comprising administering to the
4 patient a pharmaceutical preparation containing an effective dosage amount of YG-Product,
5 YGG-Product, Purified Leukocyte Dialysate Subfraction, or a combination thereof.

1 18. (Canceled)